Mircea Tesileanu

Mircea Tesileanu is a Research Fellow in the Department of Neurosurgery at the Yale School of Medicine, Yale University. His primary focus is on molecular and epigenetic research in neuro-oncology, particularly investigating DNA methylation profiles and their prognostic significance in brain tumors. He also analyzes regulatory processes and drug development through the lens of oncology assessments by organizations like the European Medicines Agency (EMA).

Education:

• PhD in Neuro-Oncology, Erasmus MC (2023)
• MSc in Neuroscience, Erasmus MC (2017)
• MD in Medicine, Erasmus MC (2017)

Research interests center on the interplay between molecular markers (e.g., IDH mutations, MGMT promoter methylation) and clinical outcomes in gliomas and astrocytomas. His work emphasizes optimizing treatment strategies and understanding histological variability in tumors. He collaborates extensively with international groups like the European Organisation for Research and Treatment of Cancer (EORTC) and contributes to pivotal trials such as CATNON and TAVAREC.

His recent publications highlight analyses of EMA drug assessments, post-hoc trial evaluations, and molecular biomarker studies. No scientific awards are listed in the provided information.

Advising and grants: While no formal advisees are noted, Dr. Tesileanu’s research contributions to high-impact clinical trials (e.g., CATNON, TAVAREC) reflect his role in advancing translational research. He is part of the Verhaak Lab, which focuses on genomic and epigenomic analyses of brain tumors, located at Sterling Hall of Medicine in New Haven.